Protalix Ltd.

Hadasit Medical Research Services and Development Ltd.

Uri Hanania

Yoseph Shaaltiel

Tali Kizhner

Avidor Shulman

Svetlana Gingis-Velitski

Tami Ariel

Liat Fux

Yulia Matiuhin

Yaron Ilan

Myriam Golembo

Maor Sheva

A nucleic acid construct is disclosed which is removable after transformation. Methods of using same are disclosed as well.

Removal of constructs from transformed cells

A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising:

Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same

A method of treating a TNF Alpha associated medical condition selected from the group consisting of obesity, metabolic syndrome, diabetes and a liver disease or disorder is provided. The method comprising enterally administering to a subject in need thereof a therapeutically effective amount of plant cells expressing a TNF Alpha polypeptide inhibitor, thereby treating the TNF Alpha associated medical condition.

Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.

Nucleic acid expression constructs are provided and, more particularly, nucleic acid constructs for expression of human alpha-galactosidase in plant cells, cells expressing the nucleic acid construct, producing the human alpha-galactosidase and uses thereof.

Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.

Dry powder formulations of dNase I

An inhalable pharmaceutical composition for pulmonary administration comprising human DNase I and a liquid carrier and, more particularly, but not exclusively, to methods, liquid pharmaceutical inhalation devices and systems for the therapeutic use thereof are provided.

Growing community of inventors

Carmiel, Israel

Uri Hanania